2.1. Study Protocol
atherosclerotic cardiovascular disease, hypercholesterolemia, ASCVD
ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, HYPERCHOLESTEROLEMIA, ASCVD
The present is a prospective, multicentric, open-label, randomized controlled trial conducted at 4 outpatients endocrine clinical centers in Greece, according to a controlled, randomized, and repeated measures design from June 2022 to January 2023 (registration code: ACTRN12623000621617). Patients were eligible to participate in the present study if they were >40 years of age, had mild hypercholesterolemia (fasting LDL-C concentration between 140 and 180 mg/dL), and no indication for statin treatment (10-year atherosclerotic cardiovascular disease risk (ASCVD Risk) <7.5%). The 10-year risk was calculated in all participants using the updated ASCVD Risk Estimator Plus (found in: 